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Universal access to safe and effective contraception is an
important public health goal. Family planning and preven-
tion of unintended pregnancy are essential to securing the
well-being and autonomy of individuals, while supporting
the health and development of communities [1]. The World
Health Organization (WHO) recently undertook a process to
update its global guidance on “who” can use contraception
safely and “how” to use contraception safely and effectively
to generate the fifth edition of the WHO Medical Eligibility
Criteria for Contraceptive Use (MEC) and the third edition of
the WHO Selected Practice Recommendations for Contra-
ceptive Use (SPR). Overall, the MEC demonstrates that
contraception is remarkably safe for most people; at least
one highly effective contraceptive method is assigned a
category “1” or “2” across the majority of conditions in the
guidance, indicating no restrictions on use or that the
advantages of using a particular method generally outweigh
the theoretical or proven risks of use. Once a medically
appropriate method is identified, the SPR offers critical
guidance on safe and effective use, important for contracep-
tive management and service delivery. The major goal for
producing these evidence-based recommendations is to help☆ Disclaimer: The findings and conclusions in this report are those of the
authors and do not necessarily represent the official position of the World
Health Organization or Centers for Disease Control and Prevention.
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planning services worldwide.
While these recommendations reflect a rigorous synthesis
and interpretation of the best evidence to date and contribute
significantly to medical and public health knowledge around
the world, a number of recommendations in both the MEC
and SPR are grounded in limited to no direct evidence.
Related to safety, conducting research on whether exposure
to a contraceptive method would worsen a disease given
significant theoretical concerns (e.g., combined hormonal
contraceptive use among women with current breast cancer)
would be unethical. In other instances, no or very limited
published literature directly reports whether or not use of a
given method is associated with an important health risk or
how best to offer a contraceptive service. In the absence of
direct evidence, indirect evidence and expert opinion inform
assessments. For example, extrapolating what is known
about the safety of contraceptive methods in healthy women
to women with medical conditions can be helpful, while
taking into account relevant disease processes and how they
intersect with what is known generally about the character-
istics of methods, associated side effects and potential
complications. Even when direct evidence is available,
methodological flaws can limit interpretation. The body and
certainty of the evidence underpinning the recommendations
has increased and improved over time in response to
increased and improved contraceptive research.
Each revision of the MEC and SPR offers an opportunity
to identify current knowledge gaps and promote research
necessary to continually strengthen the guidelines [2]. As
part of the most recent revision of these guidelines, a-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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September 2014 to generate updated recommendations.
During these meetings, we identified a number of key
research questions for a variety of topics discussed during the
technical consultations. The full list of research gaps is
included in Table 1, not further prioritized. However, we
present three important topics of global relevance to national
programs and policies in greater detail: (a) intrauterine
device (IUD) initiation among women at high risk for
sexually transmitted infections (STIs); (b) bidirectional
drug–drug interactions with use of hormonal contraception
(HC) and antiretroviral therapy (ART); and (c) initiation of
progestogen-containing contraception following use of
ulipristal acetate (UPA) emergency contraception. Each
section presents some background on the public health
importance of the topic and discusses the limitations of
existing data and considerations for future rigorous research.2. IUD initiation among women at increased risk for STIs
Women who are at increased risk of STIs may also be at
increased risk of unintended pregnancy due to unprotected
intercourse, indicating a compelling need for both protection
against STIs and effective contraception. IUDs are among
the most effective methods of contraception available;
however, IUD initiation among women at increased risk
for STIs may theoretically increase risk for pelvic inflam-
matory disease (PID). PID is associated with both acute and
long-term severe complications, including sepsis, infertility,
ectopic pregnancy and chronic pelvic pain. To better
determine the balance of risks and benefits of initiating
IUDs among women at high risk for STIs, further research
is needed.
The majority of acute PID is caused by STIs, including N.
gonorrhoeae, C. trachomatis, Mycoplasma genitalium as
well as bacterial vaginosis [3]. Untreated lower genital tract
infections, most commonly N. gonorrhea and C. trachoma-
tis, can ascend into the upper genital tract, causing
endometritis, salpingitis or other forms of PID; up to 15 to
40% of women with an untreated chlamydial infections or
gonorrhea develop PID worldwide [4,5]. Women without
STIs undergoing insertion of modern copper-containing and
levonorgestrel (LNG)-releasing IUDs is associated with only
a small transient risk for PID (9.7 per 1000 women–years)
that exists primarily in the first 20 days following placement
[6]. More research is needed to determine both best methods
to ascertain individual risk for STIs and asymptomatic
infection at the time of IUD insertion and whether IUD
insertion in the presence of STIs modifies baseline risk
for PID.
While there are many epidemiologic risk factors that
contribute to the evidence base for STI screening practices, it
is unclear whether these same factors, for example, multiple
sexual partners, age, previous STI and others, impact the risk
of PID with IUD insertion [7–11]. Currently, women at highrisk for STIs can be screened for N. gonorrhea and C.
trachomatis if asymptomatic on the day of IUD insertion,
followed by later treatment if test results return positive [12].
However, in many parts of the world, STI diagnosis is
constrained by a lack of available, easy-to-perform, accurate
and inexpensive diagnostic tests. Moreover, there is an
urgent need for rapid point of care testing for STIs to allow
diagnosis and treatment in a single visit [13]. In areas where
laboratory testing is currently unavailable, development
and validation of better methods for screening by history or
other innovative approaches are also necessary. Strength-
ened STI surveillance and improved reporting of STI
prevalence rates in general populations as well as high-risk
subgroups is critical to the larger public health goal of STI
control worldwide but also essential for the design and
evaluation of potential risk prediction models at the time of
IUD insertion [14].
A systematic review prepared as part of the process to
generate the third edition of the WHO MEC set out to
examine risk for PID among women with STIs at the time of
IUD insertion [15]. No studies were identified that directly
examined the risk of PID in a group of women with current
STIs undergoing IUD insertion compared to no insertion;
however, six studies reporting indirect evidence comparing
risk for PID among women with and without STIs at the time
of copper-bearing IUD insertion were identified. In this
report, the absolute risk of PID ranged from 0–5% among
women with STIs compared with 0–2% among women
without STIs at insertion. An additional study has since been
published that retrospectively investigated PID risk among
IUD users compared with depot medroxyprogesterone
acetate (DMPA) users attending a high-risk urban clinic
[16]. Women with a prior history of STIs were more likely to
have another STI after insertion but were not more likely to
have PID. The incidence of PID was low after IUD insertion
(2.2%) and similar to women who received DMPA.
An ideal study to determine if IUD insertion modifies the
risk for PID among women with STIs would examine the
incidence of PID among women with known STIs who were
or were not undergoing IUD insertion. Such a study would
not be ethical, as all of the women would have to be followed
untreated until they developed PID, unnecessarily exposing
them to a serious condition with significant acute and chronic
sequelae. Given this challenge, a study comparing the risk
for PID among women at high risk for STIs who
prospectively undergo IUD insertion versus no IUD
insertion offers meaningful, albeit indirect, evidence;
however, identifying an appropriate comparison group also
poses additional challenges. Because hormonal contracep-
tives such as combined oral contraceptives (COCs) or barrier
methods like the condom or diaphragm may decrease the
risk of PID, it is important to take the comparison method
into account for future studies. Ideally, information about
sexual behavior such as number of partners, frequency of
intercourse, age, condom use and other potential con-
founders should be adequately assessed and controlled for
Table 1
Research gaps identified in the development of the WHO MEC, 5th Edition and SPR, 3rd Edition.
Method Condition or practice
consideration
Unanswered research question
HC HIV 1. Among women at high risk of acquiring HIV infection who are using HC, compared with women at high risk of HIV
infection who do not use a hormonal contraceptive method, to what extent do patterns of condom use explain associations
between hormonal contraceptive use and risk of HIV acquisition?
CHC Breastfeeding 1. Does the use of combined hormonal as compared to non-HC among women who are fully or near fully breastfeeding
during the first 6 weeks postpartum affect lactation performance, infant development, infant health or maternal health?
Postabortion 1. Does immediate use of CHC following a medical or surgical abortion increase the risk of venous thromboembolism
(compared to users of non-HC and/or interval initiation)?
CVR Method initiation 1. How long after the start of the menstrual cycle can a woman initiate use of the combined hormonal vaginal ring without
needing to use a backup method of contraception?
POI HIV 1. Are there differences in behavioral and/or socioeconomic characteristics among women who use injectable
contraceptive methods, compared with women who use other contraceptive methods, that modify any associations
between contraceptive method use and HIV acquisition risk?
Method continuation 1. Does the timing of return to fertility after a DMPA subcutaneous injection differ compared with the timing following a
DMPA intramuscular injection?
Problems during use 1. Are there any adverse effects to the woman if DMPA-intramuscular is inadvertently administered subcutaneously?
Implants HIV 1. Among women at high risk for HIV, is the risk of acquiring HIV infection increased among women who use implants
compared with women who use a nonhormonal method of contraception?
Drug Interactions 1. Does the use of the ARV, EFV, among women using LNG- or ENG-releasing implants decrease the contraceptive
efficacy of the LNG- or ENG-releasing implant?
2. Does the concomitant use of antituberculosis medication among women using LNG- or ENG-releasing implants
confound any drug interactions between EFV and LNG- or ENG-releasing implants?
3. Does the use of the ARV, Nevirapine, among women using LNG- or ENG-releasing implants decrease the
contraceptive efficacy of the LNG- or ENG-releasing implant?
Obesity 1. Is the effectiveness of Sino-Implant (II) decreased when used by women with increased body weight or body mass
index ≥30 kg/m2? Are results from studies conducted among Chinese women reporting on the effectiveness of
Sino-Implant (II) with varying values for body mass index generalizable to other populations?
Method continuation 1. Can Sino-implant (II) be used as an effective method of contraception for more than 4 years?
2. Does the elastomer coating of Sino-Implant (II) affect its biomechanical properties?
IUD STIs 1. Can an algorithm identify whether risk of acquiring PID is increased with IUD insertion?
• Are women with multiple sexual partners at increased risk of PID if they undergo IUD insertion?
• Are women who live in a setting with high prevalences of gonorrhea or chlamydia at increased risk of PID if they
undergo IUD insertion?
• Are there other markers of individual risk for PID that can be used to screen women seeking an IUD insertion?
Method continuation 1. Does checking for the presence of an IUD string(s) improve user satisfaction with the method?
2. Does checking for the presence of an IUD string(s) increase the method's effectiveness by alerting the user when/if an
expulsion has occurred?
ECPs Breastfeeding 1. Can breastfeeding women safely use UPA for emergency contraception?
• To what extent is a breastfed infant exposed to UPA?
Drug interactions 1. Are there drug interactions between ARVs and emergency contraceptive pills (LNG, UPA or estrogen–progestogen)
that decrease the effectiveness of the emergency contraceptive pills?
2. Are there drug interactions between ARVs and emergency contraceptive pills (LNG, UPA or estrogen–progestogen)
that decrease the effectiveness of ARVs?
Obesity 1. Is UPA, compared with LNG emergency contraceptive pills, a more effective method of emergency contraception for
women who are obese (30 kg/m2)?
Problems during use 1. Is vaginal compared with oral administration of LNG/UPA more or equally effective as emergency contraception?
Starting a new method
after ECPs
1. How long should a woman wait to begin using a regular method of progestogen-containing contraception after she has
used UPA for emergency contraception?
• Does the effectiveness of UPA decrease when a progestogen-containing method is initiated?
PVR Breastfeeding 1. Does initiating the use of PVRs in women less than 4 weeks postpartum adversely affect breastfeeding performance,
infant health or infant development?
2. Is the contraceptive effectiveness of the progesterone-releasing vaginal ring dependent upon the mother fully
breastfeeding?
• What is the efficacy of the PVR among women who are practicing limited breastfeeding?
HC = hormonal contraception; CHC = combined hormonal contraception; CVR = combined vaginal ring; POI = progestogen-only injectables; IUD = intrauterine
device; ECPs = emergency contraception pills; PVR = progesterone-releasing vaginal ring; HIV = human immunodeficiency virus; STIs = sexually transmitted
infections; ARV = antiretroviral medication; UPA = ulipristal acetate; DMPA = depot medroxyprogesterone acetate; LNG = levonorgestrel; ETG = etonogestrel.
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standardized criteria for outcome ascertainment of PID is
also important to increase interpretation and comparability ofresults. Studies should also evaluate if any important
difference in risk for PID exists for particular subgroups of
women according to IUD type, comparing copper and
198 M.V. Dragoman et al. / Contraception 94 (2016) 195–201LNG-releasing devices. Finally, there is a possibility that
providers may be sensitized to identify PID in those with an
IUD in place; any potential diagnostic bias should be
accounted for in study design.3. Drug–Drug interactions: ART and HC
Sixteen million women worldwide live with HIV—most
are of reproductive age, and almost 50% are using ART. For
women living with HIV, access to and correct and consistent
use of effective contraception is critical to minimizing
maternal to child transmission of HIV by preventing
unintended pregnancy and to improving health outcomes
for these women overall. Some hormonal contraceptives and
certain antiretroviral medication (ARV) medications may be
subject to drug interactions when used concurrently,
potentially leading to uni- or bidirectional decreases in
effectiveness or increases in side effects or toxicity of either
medication.
The four major classes of antiretroviral medications
currently recommended for use in various combination for
the prevention and treatment of HIV include nucleoside
reverse transcriptase inhibitors (NRTIs), nonnucleoside
reverse transcriptase inhibitors (NNRTIs), protease inhibi-
tors (PIs) and integrase inhibitors [18]. The limited existing
body of evidence demonstrates great variability in observed
pharmacokinetic (PK) interactions among medications
within the same ARV class, across classes and according
to hormonal contraceptive method, making it difficult to
generalize any effects; additional research to better under-
stand any PK or pharmacodynamic (PD) changes and their
association with clinical outcomes is needed. NRTIs do not
appear to have significant risk for interaction with hormonal
contraceptive methods [19]. In contrast, NNRTIs are more
likely to induce the hepatic cytochrome P450 family of
oxidizing enzymes, particularly CYP 3 A4, responsible for
the metabolism of contraceptive steroids, leading to potential
interactions with certain HC that may decrease contraceptive
effectiveness. Of particular concern is efavirenz (EFV), a
potent hepatic enzyme inducer. Regimens containing EFV
are recommended by WHO as first-line treatment for adults,
adolescents and pregnant and postpartum breastfeeding
women as well as those starting ART while on antitubercu-
losis treatment [18].
Existing PK data suggest that EFV leads to decreases in
serum concentrations of both ethinyl estradiol and proges-
togen contained within COCs [20]. Similarly, decreases in
hormonal concentrations with concurrent use of EFV and
progestogen-only emergency contraceptives have been
observed [21]. Furthermore, a small PD study showed
higher ovulation rates in women taking EFV-containing
ART and COCs [20]. In contrast, other NNRTIs, including
nevirapine, etravirine and rilpivirine, do not appear to
significantly interact with COCs based on clinical, PK and
PD data [22–26]. Based primarily on PK data, theeffectiveness of DMPA is unlikely to be affected by
NNRTIs, and vice versa, but the potential for combined
toxicity in the long term has not been evaluated [27]. No
published studies have evaluated ARV drug interactions
with norethisterone enanthate.
One retrospective chart review of women using EFV-
containing ART reported increased contraceptive failure
rates among women using LNG implants. Fifteen of 121
women using EFV (12.4%) became pregnant with a mean
time between implant insertion and pregnancy of
16.4 months, while none of the 208 women using nevirapine
experienced a failure [28]. Another recently published PK
study found that a multidrug ART regimen containing
EFV-lowered etonogestrel (ENG) levels among women
using ENG implants [29]. While few case reports of
contraceptive failure exist in this context, no published
comparative studies have evaluated pregnancy rates among
ENG implant users during exposure to EFV or other ARVs,
and further research is needed to confirm findings among
LNG implant users.
Among the studied interactions of PIs and HC, PK data
show decreases in COC ethinyl estradiol and progestogen
levels with concurrent use of both ritonavir or ritonavir-
boosted PIs [30–34]. However, in women using the
combined hormonal transdermal patch, co-administration
resulted in higher progestogen levels [34]. One study found
higher progestogen levels with concurrent PI use in users of
progestogen-only pills (POPs), but data on POP levels when
used with other ARV classes, such as NNRTIs, are not
available. A study of women using ENG implants showed
higher ENG levels in women taking ritonavir-boosted
lopinavir [29].
Most of the existing data on drug interactions between
ARV and HC references PK and PD studies evaluating
single agent ARV co-administered with a hormonal
contraceptive method. These studies offer indirect but
meaningful data, particularly given the paucity of available
literature on this topic. An advantage of these studies is that
they can typically be completed in a relatively short period of
time and require small numbers of participants; however,
they can also be resource intensive, requiring inpatient or
outpatient facility monitoring and frequent serum sampling
for laboratory assays. Typical PK and PD studies include
healthy participants. Due to the study design, there can be
challenges with recruitment and also ethical concerns related
to exposing healthy individuals to potential adverse drug
effects associated with unnecessary treatments. While
discrete changes can be recorded with single agent
co-administration, in reality, women living with HIV are
routinely using multiple ARVs that may have interactions
with each other and unique interactions with HC. Extrapo-
lating the cumulative PK or PD changes from individual
studies of single agent interactions is challenging. Clearly,
there is a need to evaluate the PK and PD of common
multidrug ARV regimens and HC; however, such studies
magnify some of the recruitment and ethical challenges
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tion about PK and PD changes at different periods during HC
use, such as at initiation, periodic assessment with
achievement of steady state concentrations, especially for
long-acting methods, and during the hormone-free interval
for COCs, patch and ring is important and requires longer
follow up to better estimate pregnancy risks and other safety
concerns over time.
While PK and PD data can be useful, these results reflect
surrogate measures which may not adequately predict
important clinical outcomes [35]. Ideally, well-conducted
prospective comparative studies reporting on actual contra-
ceptive failures and outcomes related to HIV treatment status
offer a better estimation of the true effects of concurrent use
by women living with HIV. Given the heterogeneity of
effects within ARV drug classes, across classes and by
contraceptive method, such an approach to determining the
consequences of interactions is not feasible for all potential
drug–drug interactions but may be appropriate for investi-
gating those of greatest public health relevance, such as EFV
and HC. Due to issues of drug resistance and inadequate
treatment, it is not ethical to conduct a trial that would expose
women living with HIV to single agent EFV combined with
HC, and it would also not be ethical to deny control participants
treatment to any ARV or effective HC. However, a pragmatic
approach might be an observational study that measures
contraceptive failures among women using different multidrug
ARV regimens (first line containing EFV vs. second line
without) to determine clinically relevant effects. It would be
necessary to control for a number of potential confounders that
could affect the outcomes of interest, including strict adherence
to both the ARV regimen and HC and other factors (e.g., Body
mass index) that could have bearing on contraceptive and/or
ARV effectiveness. Complicating matters further, women with
HIV are also subject to other co-infections, such as tuberculosis;
this necessitates treatment with a combination of multidrug
ARV regimens and known cytochrome P450 inducers like
rifampin, requiring additional investigation. Studies should be
conducted in diverse populations of women as responses to
medication may vary according to individual characteristics
including race, ethnicity, physiology and genetics.4. Initiating progestogen-containing contraception following
use of UPA emergency contraception
UPA has been approved and marketed in several
countries as emergency contraception since 2009. It is a
selective progesterone receptor modulator effective to 120 h
after unprotected intercourse and may delay ovulation up
until the peak of the leuteinizing hormone (LH) surge
[36,37]. The WHO Guidelines Development Group priori-
tized the addition of UPA to the emergency contraceptive
methods referenced in recommendations for the latest
editions of both the MEC and SPR.To decrease future risk of unintended pregnancy at the
time of emergency contraception pill (ECP) use, prompt
initiation or continuation of a regular contraceptive
method is important. As a selective progestogen receptor
modulator, UPA binds to progestogen receptors to delay
ovulation, raising theoretical concerns that starting
progestogen-containing contraceptives (both progesto-
gen-only and combined hormonal) at the same time as
UPA administration may decrease the effectiveness of
either the progestogen-containing method, UPA or both.
Women, thus, could find themselves at increased risk for
both failed emergency protection against unintended
pregnancy and incomplete contraceptive protection during
subsequent sex acts while using a routine hormonal
contraceptive.
There are currently no published studies evaluating any
potential interactions reporting clinical outcomes of preg-
nancy; however, limited PK and PD data are published and
reported within the package label for UPA. Results from a
study where women used a COC containing ethinyl estradiol
30 mcg and LNG 150 mcg 1 day after administration of
UPA during the follicular phase or COC alone demonstrated
similar rates of ovulation suppression in both groups,
measured by follicle size, serum progesterone and estradiol
[38]. This study did not report results from women exposed
to UPA alone. Another study examined use of a POP
containing desogestrel 75 mcg taken 1 day after UPA during
the follicular phase and compared the incidence of ovulation
with the use of UPA alone [39]. Even though UPA is rapidly
absorbed, a higher incidence of ovulation in the 6 days
following desogestrel and UPA intake compared with UPA
alone was noted (45% vs. 3%, respectively), and there was
also a slower onset of cervical mucus thickening in the group
taking desogestrel and UPA compared with the group taking
desogestrel alone.
Progestogen-containing hormonal contraceptives rely on
various mechanisms of action to confer protection against
unintended pregnancy [40]. Not only is it important to
understand the effects of coadministration of UPA with all
of these methods on intermediate outcomes such as
ovulation suppression or cervical mucus thickening, but
information on actual contraceptive failure and pregnancy
rates is critical. Whether any effect is the same for methods
with systemic hormonal exposure (i.e., POP, DMPA,
implants) and primarily locally acting methods like the
LNG-releasing IUD is also unknown. Knowledge of the
duration of any effects following administration of UPA is
important to determine the best timing for initiation or
continuation of progestogen-containing methods and/or
need for and length of required backup protection. For
women wanting to start progestogen-containing hormonal
contraceptives that they must receive within a clinic setting—
such as an implant, LNG IUD or DMPA — it is important to
understand these interactions so as to not further burden women
with unnecessary delays in initiation and multiple visits to a
health care provider.
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We have elaborated on only a few of the research gaps
identified by experts during the updating process to
generate the latest editions of the WHO MEC and SPR
(Table 1). The highlighted topics and research questions
in this article are grounded in this most recent process;
however, our commentary is the third in a series of
publications promoting diverse areas for research that are
critical to better understanding safe and effective contracep-
tive use [2,41].
Both the MEC and SPR offer recommendations based on
the best evidence to date. These guidelines play an important
role in ensuring that contraceptive use is restricted with
evidence of risk, facilitated when there is evidence of safety,
and that effectiveness is maintained through correct and
consistent use. Uptake of the recommendations supports
quality family planning programs and helps health care
providers better serve women and men in their practice. We
encourage investigators to consider these research gaps when
prioritizing research planning. Results from future high-
quality studies in critical areas for research can be
incorporated into the evidence base underpinning these
recommendations, further strengthening future iterations of
these documents while continuing to promote best practices
for high-quality family planning care.References
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